GCM
CMPX icon

Graham Capital Management’s Compass Therapeutics CMPX Stock Holding History

Graham Capital Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.1K Sell
22,857
-694
-3% -$2.05K ﹤0.01% 1203
2026
Q1 		$125K Sell
23,551
-29,876
-56% -$172K ﹤0.01% 1014
2025
Q4 		$287K Buy
+53,427
New +$247K 0.01% 877

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Graham Capital Management's CMPX Position: Q2 2026 in Review

Graham Capital Management reduced its Compass Therapeutics (CMPX) stake by 2.9% in Q2 2026, selling an estimated $2.05K and leaving 22,857 shares worth $50.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1203.

Graham Capital Management first reported a position in CMPX in Q4 2025 and has held it in 3 quarters since. The position peaked at $287K in Q4 2025. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Graham Capital Management held 22,857 shares of Compass Therapeutics worth $50.1K as of Q2 2026.
  • Graham Capital Management sold 694 Compass Therapeutics shares in Q2 2026, an estimated $2.05K.
  • Compass Therapeutics made up ﹤0.01% of Graham Capital Management's portfolio in Q2 2026, its #1203 holding.
  • Graham Capital Management first reported a position in Compass Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Graham Capital Management's Compass Therapeutics position peaked at $287K in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.